Predictive value in the analysis of RNASEL genotypes in relation to prostate cancer

Abstract

BACKGROUND:We would like to compare the different RNASEL genotypes with the stage of the cancer using parameters such as PSA levels, Gleason score and T-stage, and to develop a clinical protocol for the monitoring of the disease for trying a better evolution of the patient. METHODS:A total of 231 patients with sporadic prostate cancer and 100 of controls were genotyped in RNASEL gene by sequencing the exons 1 and 3. A survey of clinical information was collected by a specialist following the Helsinki protocol. All patients and controls were interviewed by a researcher and signed their informed consent to participation in the study, which was approved by Ethics Committee of the hospital. The genetic information was processed and collected with an ABI PRISM Genetic Analyser 3130 using SeqScape software v.2.6. All the patients were analysed by comparing the genetic and clinical data. w 2 -tests, Monte Carlo, Fisher tests and contigency tables were performed using SPSS v.15.0 and ARLEQUIN v.3.5 software on patient population.RESULTS: Significant differences were found only between patients and controls in D541E, R461Q and I97L genotypes, the remainder of the variants did not seem relevant to our population in contrast to other populations, such as north-Caucasians, Afro Americans and Ashkenazi Jews. The genotypes associated with the worst prognoses are G/G in D541E, A/A in R462Q and A/G in I97L. The controls were included in our study to determine an approximation of the genotype in our population compared with the patients, but they did not account for the statistical process. CONCLUSIONS:The genetic profile of patients with this cancer combined with other parameters could be used as a prognosis factor in deciding to give more radical and frequent treatments, depending on personal genotype.

Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk

“…mRNA expression levels in the TMPRSS2-ERG fusion gene and ERG have been found to be associated with an aggressive phenotype and have a prognostic value and proved to serve as molecular markers of PCa progression [15]. Conversely, there is scarce data about mRNA expression levels in RNASEL, MSR1, KLK3, AR, and ELAC2 in PCa [6,[16][17][18][19]. Only a study has been performed to measure mRNA expression levels in 14 genes, with statistically significant differences (P o 0.05) found for PCA3, PSMA, PSGR, KLK3, GOLM1, CDH1, and SPINK1 genes in PCa [20].…”

“…Some genes such as RNASEL, ELAC2 (elaC ribonuclease Z 2), MSR1, AR, and KLK3 have been traditionally associated with PCa and disease severity [6,7], and we focused on these traditional genes to perform the deeper analysis of the present study. These 3 genes are involved in pathways critical to DNA damage response (ELAC2), apoptosis (2 0 -5 0 -oligoisoadenlyate-synthetase-dependent RNase L [RNASEL]), and innate immunity (macrophage scavenger receptor 1 [MSR1] and [RNASEL]) and identified in linkage-critical regions, conferring risk for PCa [8].…”

Prioritization of potential candidate disease genes by topological similarity of protein–protein interaction network and phenotype data

“…CBX7, as a novel PcG protein controlling the growth of normal cells, is highly expressed in three prostate cancer cell lines and is upregulated in the normal prostate [36]. Finally, the RNASEL [37], ELAC2 [38], genes are reported to be related to prostate cancer. These data show that our predictive method can discover novel disease genes beyond the original disease gene set.…”

Evaluation of Xenotropic Murine Leukemia Virus and its R426Q Polymorphism in Patients with Prostate Cancer in Kerman, Southeast of Iran

“…The risk of prostate cancer for men in their lifetime is 1 in 6 cases, which is statistically significant and the high incidence of this cancer in middle-aged men is remarkable compared to other cancers (Alvarez et al, 2012). According to recent studies, 30-50 percent of men over age 50 are infected with prostate cancer.…”